67.98 -0.55 (-0.81%)
After hours: 4:11PM EDT
|Bid||68.49 x 900|
|Ask||68.48 x 900|
|Day's Range||66.99 - 69.03|
|52 Week Range||53.61 - 74.15|
|Beta (3Y Monthly)||1.62|
|PE Ratio (TTM)||137.63|
|Earnings Date||Jan 22, 2019 - Jan 28, 2019|
|Forward Dividend & Yield||1.12 (1.66%)|
|1y Target Est||78.94|
Get Some Much will be made of this morning's equity market selloff. There will be calls made on both sides. Bulls will state their case. Bears will make theirs. Financial TV will be full of them, and a lot of them, you and I know will be full of something else.
Wall Street analysts expect Thermo Fisher Scientific’s (TMO) third-quarter revenues to increase ~11.5% to $5.7 billion—compared to its revenues of $5.1 million during the third quarter of 2017. The adjusted EPS is estimated to be $2.55 for the third quarter—compared to the adjusted EPS of $2.31 in the third quarter of 2017.
Of the five analysts covering NovoCure (NVCR) stock in October, two have given it a “strong buy,” and three have given it a “buy.” The mean rating for NovoCure is 1.6 with a target price of $56.50. That implies an upside potential of 24.4% over its trading price of $45.42 on October 18.
NovoCure’s (NVCR) gross income is expected to rise 28.22% to $44.82 million in the third quarter of 2018. Its gross margin is expected to contract from 69.76% in the third quarter of fiscal 2017 to 68.7% in the third quarter of fiscal 2018. NovoCure’s gross margins for fiscal 2018 and fiscal 2019 are expected to be 67.97% and 72.72%, respectively.
ABBOTT PARK, Ill., Oct. 19, 2018 /PRNewswire/ -- Abbott (ABT) announced today that the HeartMate 3™ Left Ventricular Assist Device (LVAD) has received U.S. Food and Drug Administration (FDA) approval as a destination therapy for people living with advanced heart failure. With the approval, physicians can now offer the HeartMate 3 system to patients not eligible for a transplant who will live with their device for the rest of their lives. More than 5.7 million Americans suffer from heart failure, and there are approximately 915,000 new patients diagnosed with the disease annually.
On October 17, Zimmer Biomet Holdings (ZBH) stock closed at $128.32, an ~23.0% increase from its 52-week low of $104.28 on April 6. On October 16, Zimmer Biomet’s stock price recorded ~3.38% growth to reach $127.68 from its closing price of $123.50 on October 15. On September 21, Zimmer Biomet hit its 52-week high of $134.55. Segment revenue trends
Zimmer Biomet Holdings (ZBH) plans to release its third-quarter earnings on October 26. Wall Street analysts expect ZBH to generate revenues of $1.8 billion in the third quarter.
The U.S. health care company Abbott Laboratories (ABT) reported strong third-quarter results before the opening bell on Wednesday, though shares declined 1.01% to $70.23. On a GAAP basis, earnings per share were 31 cents. Warning! GuruFocus has detected 7 Warning Sign with ABT.
In a note to clients on Tuesday, Barclays analyst Kristen Stewart highlighted the investment bank's favorite picks in the red-hot sector. Barclays is particularly bullish on shares of Abbot Labs, due to the company's promising product pipeline and "favorable mix of businesses." Stewart's 12-month price forecast on shares of the Chicago-based company at $80 imply a near 16% upside from current levels.
Of the total 25 analysts covering Boston Scientific (BSX) in October 2018, 22 analysts have given Boston Scientific a “buy” or higher rating, and three analysts have given Boston Scientific a “hold” rating. The mean rating for Boston Scientific is 1.52 with a target price of $41.57, which implies an upside potential of 9.4% over Boston Scientific’s closing price of $38.0 on October 17, 2018.
Boston Scientific’s (BSX) gross income is expected to increase by 9.26% from $1.58 billion in the third quarter of fiscal 2017 to $1.73 billion in the third quarter of fiscal 2018. Its gross margin is expected to expand from 71.33% for the third quarter of fiscal 2017 to 71.95% for the third quarter of fiscal 2018.
The vote in Wentworth, the Sydney constituency previously held by former prime minister Malcolm Turnbull, is one of the wealthiest in Australia and has never been held by the opposition Labor party. as Liberal leader and prime minister in August has angered many supporters of the government, which retains a one-seat majority in parliament.
The Dow trades lower as a slump in shares of IBM prevents the index from a significant move into positive territory.
For the most part, the stock market hung onto most of its gains following Tuesday’s monstrous move. As we get into earnings seasons though, investors will have to fight against both market-wide volatility and giant moves in individual stocks.10 Marijuana Stocks for the Canadian 'Pot Rush'
Within Structural Heart, growth was driven by several product areas across Abbott's (ABT) broad portfolio, including AMPLATZER PFO Occluder and MitraClip.
ABBOTT PARK, Ill., Oct. 17, 2018 /PRNewswire/ -- For someone experiencing cardiac symptoms in the emergency room, every minute matters as physicians determine whether someone is having a heart attack. More than seven billion diagnostic tests are run in the U.S. each year to help physicians make accurate, timely decisions about a person's medical treatment.2 Point-of-care diagnostic tests, that can often provide results within minutes, are used globally as hospitals face increased pressures to address overcrowding in emergency rooms and longer wait times.
This is an increase over the company’s earnings per share of 66 cents during the same time last year. It also matches Wall Street’s earnings per share estimate for the quarter, but couldn’t keep ABT stock from falling today. During the third quarter of 2018, Abbott Laboratories reported net income of $563 million.
Investing.com - Abbott Labs (NYSE:ABT) reported third quarter earnings that beat analyst's expectations on Wednesday and revenue that topped forecasts.